Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 7 | 2023 | 23 | 2.600 |
Why?
|
| Rhinitis | 6 | 2023 | 18 | 2.490 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 16 | 1.640 |
Why?
|
| Endoscopy | 7 | 2023 | 28 | 0.960 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 9 | 0.900 |
Why?
|
| Nasal Polyps | 1 | 2023 | 6 | 0.760 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 23 | 0.760 |
Why?
|
| Humans | 22 | 2023 | 5837 | 0.710 |
Why?
|
| Chronic Disease | 6 | 2023 | 71 | 0.620 |
Why?
|
| Retrospective Studies | 10 | 2023 | 584 | 0.620 |
Why?
|
| Osteoblastoma | 1 | 2018 | 3 | 0.550 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2018 | 10 | 0.540 |
Why?
|
| Ethmoid Sinus | 1 | 2017 | 1 | 0.520 |
Why?
|
| Lacrimal Apparatus | 1 | 2017 | 1 | 0.520 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 14 | 0.520 |
Why?
|
| Stents | 1 | 2017 | 11 | 0.520 |
Why?
|
| Optical Imaging | 1 | 2016 | 1 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 29 | 0.490 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 24 | 0.490 |
Why?
|
| Sarcoma | 1 | 2014 | 19 | 0.410 |
Why?
|
| Treatment Outcome | 6 | 2023 | 601 | 0.400 |
Why?
|
| Otolaryngology | 2 | 2020 | 10 | 0.320 |
Why?
|
| Female | 11 | 2021 | 3346 | 0.320 |
Why?
|
| Male | 10 | 2021 | 3399 | 0.310 |
Why?
|
| Laryngeal Neoplasms | 2 | 2021 | 4 | 0.310 |
Why?
|
| Middle Aged | 7 | 2021 | 1775 | 0.230 |
Why?
|
| Nose | 3 | 2021 | 9 | 0.220 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 74 | 0.210 |
Why?
|
| Nasal Obstruction | 1 | 2023 | 1 | 0.190 |
Why?
|
| Rhinoplasty | 1 | 2023 | 4 | 0.190 |
Why?
|
| Skull Base | 2 | 2021 | 9 | 0.190 |
Why?
|
| Young Adult | 3 | 2018 | 421 | 0.180 |
Why?
|
| Adolescent | 3 | 2018 | 488 | 0.180 |
Why?
|
| Mometasone Furoate | 1 | 2022 | 3 | 0.180 |
Why?
|
| Survival Rate | 3 | 2021 | 60 | 0.180 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 5 | 0.180 |
Why?
|
| Adult | 6 | 2023 | 1670 | 0.170 |
Why?
|
| Microbiota | 2 | 2018 | 19 | 0.170 |
Why?
|
| Radiology | 1 | 2021 | 5 | 0.170 |
Why?
|
| Encephalocele | 1 | 2021 | 4 | 0.170 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 9 | 0.170 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 4 | 0.160 |
Why?
|
| Child | 5 | 2021 | 339 | 0.160 |
Why?
|
| Epistaxis | 1 | 2020 | 8 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 11 | 0.160 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.160 |
Why?
|
| Urban Health Services | 1 | 2020 | 6 | 0.160 |
Why?
|
| Airway Management | 1 | 2020 | 12 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 19 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 32 | 0.160 |
Why?
|
| Smoking | 1 | 2020 | 47 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 23 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 24 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 30 | 0.150 |
Why?
|
| Nasal Surgical Procedures | 1 | 2019 | 1 | 0.150 |
Why?
|
| Drug-Eluting Stents | 1 | 2019 | 3 | 0.150 |
Why?
|
| Steroids | 1 | 2019 | 6 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2020 | 75 | 0.150 |
Why?
|
| Craniopharyngioma | 1 | 2018 | 1 | 0.140 |
Why?
|
| Sphenoid Bone | 1 | 2018 | 1 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 2 | 0.140 |
Why?
|
| Firmicutes | 1 | 2018 | 3 | 0.140 |
Why?
|
| Bacteroidetes | 1 | 2018 | 3 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 7 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 31 | 0.140 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 30 | 0.140 |
Why?
|
| Osteoma | 1 | 2018 | 3 | 0.140 |
Why?
|
| Fibroma, Ossifying | 1 | 2018 | 3 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 7 | 0.140 |
Why?
|
| Rhinitis, Allergic | 1 | 2018 | 4 | 0.140 |
Why?
|
| Lymphoma | 1 | 2018 | 8 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 62 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 5 | 0.130 |
Why?
|
| Pseudomonas Infections | 1 | 2017 | 8 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 150 | 0.130 |
Why?
|
| Cadaver | 1 | 2017 | 79 | 0.130 |
Why?
|
| California | 1 | 2014 | 16 | 0.100 |
Why?
|
| Incidence | 1 | 2014 | 165 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 333 | 0.100 |
Why?
|
| Hair Cells, Auditory | 1 | 2010 | 1 | 0.080 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 1 | 0.080 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2010 | 1 | 0.080 |
Why?
|
| Actinomycosis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Meningitis, Bacterial | 1 | 2010 | 1 | 0.080 |
Why?
|
| Temporal Bone | 1 | 2010 | 4 | 0.080 |
Why?
|
| Encephalitis | 1 | 2010 | 6 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 15 | 0.080 |
Why?
|
| Aged | 3 | 2021 | 1860 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2021 | 154 | 0.070 |
Why?
|
| United States | 2 | 2021 | 502 | 0.070 |
Why?
|
| Nasal Septum | 1 | 2023 | 1 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 5 | 0.050 |
Why?
|
| Temperature | 1 | 2023 | 17 | 0.050 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2021 | 3 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2021 | 9 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 411 | 0.040 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2021 | 3 | 0.040 |
Why?
|
| Petrous Bone | 1 | 2021 | 3 | 0.040 |
Why?
|
| Laryngectomy | 1 | 2021 | 4 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 12 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 37 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 51 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 67 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 54 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 14 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 30 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 59 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 18 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 63 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 65 | 0.040 |
Why?
|
| Air | 1 | 2018 | 3 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 4 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 16 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 14 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Biodiversity | 1 | 2018 | 7 | 0.040 |
Why?
|
| SEER Program | 1 | 2018 | 4 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 181 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 157 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 53 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 129 | 0.030 |
Why?
|
| Cranial Nerve Diseases | 1 | 2017 | 1 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 138 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2010 | 1 | 0.020 |
Why?
|
| Hearing Tests | 1 | 2010 | 1 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2010 | 3 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 6 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 36 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 62 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 53 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 122 | 0.020 |
Why?
|
| Mice | 1 | 2010 | 465 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 1349 | 0.020 |
Why?
|